Beigene LTD. – American Depositary Shares (NASDAQ:BGNE) Stock Is Shorted Less

May 17, 2018 - By Tina Thibodeau

BeiGene, Ltd. (NASDAQ:BGNE) Logo

The stock of Beigene LTD. – American Depositary Shares (NASDAQ:BGNE) registered a decrease of 3.93% in short interest. BGNE’s total short interest was 2.03M shares in May as published by FINRA. Its down 3.93% from 2.12 million shares, reported previously. With 284,100 shares average volume, it will take short sellers 7 days to cover their BGNE’s short positions. The short interest to Beigene LTD. – American Depositary Shares’s float is 12.02%.

The stock increased 3.63% or $6.62 during the last trading session, reaching $189.11. About 178,793 shares traded. BeiGene, Ltd. (NASDAQ:BGNE) has risen 354.57% since May 17, 2017 and is uptrending. It has outperformed by 343.02% the S&P500.

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The company has market cap of $10.15 billion. The companyÂ’s clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations. It currently has negative earnings. The Company’s preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications.

More important recent BeiGene, Ltd. (NASDAQ:BGNE) news were published by: Nasdaq.com which released: “BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Chinese Patients with Ovarian Cancer” on May 17, 2018, also Streetinsider.com published article titled: “BeiGene, Ltd. (BGNE) PT Raised to $225 at Maxim Group on China PARP Study”, Globenewswire.com published: “BeiGene Reports First Quarter 2018 Financial Results” on May 09, 2018. More interesting news about BeiGene, Ltd. (NASDAQ:BGNE) was released by: Nasdaq.com and their article: “BeiGene Appoints Senior Pharmaceutical Executive Dr. Xiaobin Wu as General Manager of China and President of …” with publication date: May 01, 2018.

BeiGene, Ltd. (NASDAQ:BGNE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.